Comparison of Goserelin Acetate and Zoladex® in Prostate Cancer Treatment

This study focuses on comparing two treatments for locally advanced or metastatic prostate cancer: LY01022 and Zoladex®. The goal is to understand how these treatments work in the body, their effects, and their safety. The study involves 20-24 patients who will be randomly assigned to receive either LY01022 or Zoladex®. This research is important as it could help improve treatment options for prostate cancer patients, providing valuable insights into the effectiveness and safety of these treatments. Participants in this study will receive a single injection of either LY01022 or Zoladex®. Blood samples will be collected to assess how the body processes these treatments, specifically looking at changes in plasma goserelin concentration. The study also evaluates the safety of these treatments, as outlined in the study protocol. The results of this study could potentially lead to better care for patients with prostate cancer.